BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Figure 6. Actuarial prostate specific antigen (PSA) relapse-free survival (RFS) according pre-treatment hormones. PSA-RFS is 76.1%, for patients cohort being on pre-treatment hormones and 72.6% for patients not on hormone therapy (p=0.107) (solid line not on hormones; dashed line on hormones).





Right arrow Return to article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS